Results 201 to 210 of about 124,717 (304)

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

The tumor microenvironment's role in the response to immune checkpoint blockade. [PDF]

Nat Cancer
Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, Boussiotis VA.   +6 more
europepmc   +1 more source

Mapping Genetic Regulation of Transcription to Identify Functional Variants and Genes Associated with Pancreatic Cancer Risk

Advanced Science, EarlyView.
Integration of a pancreatic eQTL map with a GWAS meta‐analysis identifies 82 putative functional variants and 15 genes. The association between rs11102484 and pancreatic cancer risk is observed in a total of 5699 cases and 8467 controls. The G allele of rs11102484 weakens ZNF263 binding and the silencer‐promoter interaction, thereby increasing ST7L ...
Xiaoyang Wang, Hui Geng, Zhengyan Yao, Yuan Jiang, Can Chen, Zequn Lu, Shuangshuang Tian, Ming Zhang, Ruiyan Liu, Chenxi Feng, Bin Li, Xiaoping Miao, Jianbo Tian, Shaokai Zhang, Ying Zhu   +14 more
wiley   +1 more source

Toxicity and treatment discontinuation with adjuvant immune checkpoint blockade: a correspondence. [PDF]

Int J Surg
Zhong R, Huang L, Tang P.
europepmc   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Heterogeneity-optimized method for predicting immune checkpoint blockade response. [PDF]

Sci Rep
Liang J, Guo Q, Xiang S, Wang Y, Li J.
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Bridging innate and adaptive tumor immunity: cGAS-STING pathway activation to potentiate immune checkpoint blockade. [PDF]

J Exp Clin Cancer Res
Li Z, Zheng W, Liu Y, Cao R, Wei J, Jia H.   +5 more
europepmc   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

Advanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang, Kaixiong Tao, Zhenyu Lin, Tao Zhang   +12 more
wiley   +1 more source

Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma. [PDF]

Nat Commun
Liu X, Liu Z, Zhu C, Kobayashi T, Lei PJ, Shi Y, Yuan D, Wang J, Li M, Matsui A, Mafra K, Ando T, Kojo K, Schleinhege R, Miyazaki K, Huang P, Kuang M, Bod L, Duda DG.   +18 more
europepmc   +1 more source